Biolight Ltd. said Tuesday that Menorah-Mivtachim Holdings had purchased 5 million shares, or 13 percent, of the company for NIS 20 million.
By MATTHEW KRIEGER
Biolight Ltd. said Tuesday that Menorah-Mivtachim Holdings had purchased 5 million shares, or 13 percent, of the company for NIS 20 million.
With the purchase, Menorah-Mivtachim, a securities and insurance firm, became the principal shareholder of Biolight, surpassing Prisma Investment House, which still owns about 10% of the company. Biolight, a life-sciences investment company, has four subsidiaries including Ioptima, which is designing glaucoma treatments using laser-based technology, and Obecure, which is developing drugs to help battle weight control.
if(catID != 151){
var cont = `Take Israel home with the new Jerusalem Post Store